DexCom Set for Q4 Earnings; Analysts Project Positive EPS Growth

In the upcoming Q4 earnings report, DexCom is projected to improve its EPS to $0.51, a positive sign for investors. Analysts remain bullish on the stock amidst a 32.7% share decline over the past year, despite exceeding revenue expectations.

Date: 22-01-2025

AI Rating: 7

Earnings Per Share (EPS)
DexCom is expected to report an EPS of $0.51 for Q4, a slight increase from last year's $0.50. The projected EPS for fiscal 2024 is $1.70, an 11.8% increase from $1.52 in fiscal 2023, and analysts anticipate further growth to $2 for fiscal 2025, indicating a robust average increase year over year.

Revenue Growth
The company reported revenue of $994.2 million for the last quarter, exceeding expectations and marking a 2% year-over-year growth. For fiscal 2024, DexCom has maintained its revenue guidance to be between $4 billion and $4.05 billion, representing an 11% to 13% organic growth. This consistent revenue uptick may positively impact investor sentiment.

Profit Margins
DexCom expects a non-GAAP gross profit margin of approximately 63%, a non-GAAP operating margin of around 20%, and an adjusted EBITDA margin of roughly 29%. These metrics suggest solid profitability and operational efficiency, which are favorable for investors.

Despite suffering a 32.7% decline in share value over the past year, DexCom's commitment to growth, reflected through its projected EPS and revenue goals alongside strong profit margins, continues to attract a

Stocks: DXCM